汇宇制药（688553）披露HY-1016缓释注射液获临床试验申请受理通知书，4月21日股价下跌2.06%

中金财经

Apr 22

　　h2,h3,h4{padding: 10px 0;font-size: 16px;line-height: 30px;color:#262626;font-weight: 600;}h2{border-bottom: 1px solid #d8dee4; padding-bottom: 0.3em}.article_content ul{padding-left:22px;}截至2026年4月21日收盘，汇宇制药(688553)报收于19.0元，较前一交易日下跌2.06%，最新总市值为80.48亿元。该股当日开盘19.25元，最高19.43元，最低18.61元，成交额达1.89亿元，换手率为2.9%。近日，四川汇宇制药股份有限公司全资子公司四川汇宇海玥医药科技有限公司收到国家药品监督管理局签发的《受理通知书》，其申报的HY-1016缓释注射液用于治疗子宫内膜异位症的临床试验申请已获受理。该药品为含地诺孕素的新剂型、新给药途径，旨在减少用药频率、提高用药依从性。地诺孕素片已在多个国家和地区上市，国内已有原研及仿制药获批。药品研发存在周期长、审批环节多等不确定性风险。最新公告列表《自愿披露HY-1016缓释注射液获得药物临床试验申请受理通知书的公告》为证券之星据公开信息整理，由AI算法生成(网信算备310104345710301240019号)，不构成投资建议。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2629806104"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2629806104\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2629806104?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-04-22 08:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2629806104","market":"fut","top_or_hot":-1,"title":"汇宇制药（688553）披露HY-1016缓释注射液获临床试验申请受理通知书，4月21日股价下跌2.06%","media":"中金财经","content":"<html><body><p>　　h2,h3,h4{padding: 10px 0;font-size: 16px;line-height: 30px;color:#262626;font-weight: 600;}h2{border-bottom: 1px solid #d8dee4; padding-bottom: 0.3em}.article_content ul{padding-left:22px;}截至2026年4月21日收盘，<a href=\"https://laohu8.com/S/688553\">汇宇制药</a>(688553)报收于19.0元，较前一交易日下跌2.06%，最新总市值为80.48亿元。该股当日开盘19.25元，最高19.43元，最低18.61元，成交额达1.89亿元，换手率为2.9%。近日，四川汇宇制药股份有限公司全资子公司四川汇宇海玥医药科技有限公司收到国家药品监督管理局签发的《受理通知书》，其申报的HY-1016缓释注射液用于治疗子宫内膜异位症的临床试验申请已获受理。该药品为含地诺孕素的新剂型、新给药途径，旨在减少用药频率、提高用药依从性。地诺孕素片已在多个国家和地区上市，国内已有原研及仿制药获批。药品研发存在周期长、审批环节多等不确定性风险。最新公告列表《自愿披露HY-1016缓释注射液获得药物临床试验申请受理通知书的公告》为证券之星据公开信息整理，由AI算法生成(网信算备310104345710301240019号)，不构成投资建议。 </p></body></html>","source":"zhongjincaijing_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>汇宇制药（688553）披露HY-1016缓释注射液获临床试验申请受理通知书，4月21日股价下跌2.06%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n汇宇制药（688553）披露HY-1016缓释注射液获临床试验申请受理通知书，4月21日股价下跌2.06%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-22 08:03 北京时间&nbsp;&nbsp;&nbsp;<a href=http://sc.stock.cnfol.com/gushiyaowen/20260422/32162638.shtml><strong>中金财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>h2,h3,h4{padding: 10px 0;font-size: 16px;line-height: 30px;color:#262626;font-weight: 600;}h2{border-bottom: 1px solid #d8dee4; padding-bottom: 0.3em}.article_content ul{padding-left:22px;}截至2026年4月21...</p>\n\n<a href=\"http://sc.stock.cnfol.com/gushiyaowen/20260422/32162638.shtml\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688553","symbol_name":"汇宇制药-W","start_time":0,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260422/32162638.shtml","article_id":"2629806104","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2629806104","pubTimestamp":1776816233,"columns":[],"sourceInfo":{"source_id":"zhongjincaijing_highlight","name":"中金在线"},"weMediaInfo":null,"summary":"h2,h3,h4{padding: 10px 0;font-size: 16px;line-height: 30px;color:#262626;font-weight: 600;}h2{border-bottom: 1px solid #d8dee4; padding-bottom: 0.3em}.article_content ul{padding-left:22px;}截至2026年4月21日收盘，汇宇制药报收于19.0元，较前一交易日下跌2.06%，最新总市值为80.48亿元。该股当日开盘19.25元，最高19.43元，最低18.61元，成交额达1.89亿元，换手率为2.9%。近日，四川汇宇制药股份有限公司全资子公司四川汇宇海玥医药科技有限公司收到国家药品监督管理局签发的《受理通知书》，其申报的HY-1016缓释注射液用于治疗子宫内膜异位症的临床试验申请已获受理。","collect":0,"end_time":0,"defaultTopTitle":"cnfol.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688553":"汇宇制药-W","BK4161":"工业机械","BK0239":"医药制造","HY":"Hyster-Yale Materials Handling C"},"translate_title":"Huiyu Pharmaceutical (688553) disclosed that HY-1016 sustained-release injection received a notice of acceptance of clinical trial application, and its share price fell by 2.06% on April 21","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688553":1.5,"HY":1.5},"content_text":"h2,h3,h4{padding: 10px 0;font-size: 16px;line-height: 30px;color:#262626;font-weight: 600;}h2{border-bottom: 1px solid #d8dee4; padding-bottom: 0.3em}.article_content ul{padding-left:22px;}截至2026年4月21日收盘，汇宇制药(688553)报收于19.0元，较前一交易日下跌2.06%，最新总市值为80.48亿元。该股当日开盘19.25元，最高19.43元，最低18.61元，成交额达1.89亿元，换手率为2.9%。近日，四川汇宇制药股份有限公司全资子公司四川汇宇海玥医药科技有限公司收到国家药品监督管理局签发的《受理通知书》，其申报的HY-1016缓释注射液用于治疗子宫内膜异位症的临床试验申请已获受理。该药品为含地诺孕素的新剂型、新给药途径，旨在减少用药频率、提高用药依从性。地诺孕素片已在多个国家和地区上市，国内已有原研及仿制药获批。药品研发存在周期长、审批环节多等不确定性风险。最新公告列表《自愿披露HY-1016缓释注射液获得药物临床试验申请受理通知书的公告》为证券之星据公开信息整理，由AI算法生成(网信算备310104345710301240019号)，不构成投资建议。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}